WHO Pandemic Talks Advance on Sharing Pathogen Samples and Benefits
World Health Organization member states have advanced negotiations on how countries will share pathogen samples and genetic-sequence data, while ensuring that the benefits of research, tests, vaccines and medicines return to the countries and communities that contribute the information. The talks took place ahead of a United Nations General Assembly meeting on pandemics and are part of the continuing work to implement the WHO Pandemic Agreement.
The issue is technical, but its consequences are global. When a new virus is detected, laboratories need access to samples and sequence data to identify mutations, develop diagnostics and begin vaccine or treatment research. Countries where pathogens are first found want assurance that sharing biological material will not leave them without access to the products developed from it. The negotiations are intended to create clearer rules before the next emergency.
What pathogen access and benefit sharing means
Pathogen access refers to the movement of samples, laboratory material and related information for public-health research. Benefit sharing covers what happens after that material helps produce something valuable, such as a diagnostic test, vaccine, antiviral medicine or scientific platform. Benefits can include access to products, technology transfer, funding, training and participation in research.
The system must balance speed with fairness. Scientists need rapid access to data during an outbreak, but countries also need safeguards about consent, ownership, privacy and use. If governments fear that sharing will bring little benefit or could expose them to commercial exploitation, they may delay cooperation. Delays can cost lives when a pathogen is spreading quickly.
Why the talks are difficult
Countries have different scientific capacities, legal systems and commercial interests. Some are major research and manufacturing hubs; others may provide samples but have limited laboratories or purchasing power. Governments must also decide how to handle sequence data that can be shared digitally without moving a physical sample. A workable arrangement must be clear enough for laboratories and companies but flexible enough to cover new technologies.
There are also questions about transparency. Researchers need to know what material is available and under what conditions. Communities need confidence that samples are not being collected without permission or used in ways that violate local expectations. Companies need predictable rules before investing in development. The negotiations therefore connect public health, intellectual property, ethics and international law.
What has been agreed—and what has not
The September meeting advanced negotiations; it did not create an instantly operational global distribution system. WHO member states still have to settle unresolved language, adopt the annex and put national procedures in place. The Pandemic Agreement itself was adopted in 2025, but the pathogen access and benefit-sharing annex remains a central workstream.
It is also important not to describe the process as a mechanism that gives WHO control over national laboratories or public-health decisions. The work is being negotiated by member states. Implementation will depend on governments, laboratories, manufacturers and international partners agreeing on the details and providing the resources needed to make them work.
Why it matters before the next outbreak
The COVID-19 pandemic showed that speed, manufacturing capacity and equitable access are connected. A vaccine developed quickly is not enough if countries cannot obtain doses, tests or protective supplies. A fairer system could encourage earlier sharing and make it easier to coordinate research, while also recognising the countries that contribute samples and knowledge.
The next stage will be watched at the UN General Assembly and in future WHO meetings. Governments will need to explain how the proposed system would operate during a real outbreak, how benefits would be allocated and how compliance would be measured. The agreement’s credibility will rest on those practical details, not on the headline alone.
There is also a trust question. Lower-income countries have often argued that global health rules ask them to share samples quickly while leaving them last in line for tests, vaccines or medicines. Higher-income countries and manufacturers, meanwhile, need workable rules that protect legitimate research and investment. Negotiators will need language that recognises both concerns without allowing commercial secrecy to block emergency cooperation.
Public communication will matter after an annex is adopted. Laboratories, ministries and companies must know which agreements apply, where data can be stored and how disputes are resolved. A rule that looks clear in diplomatic language but is confusing at the bench will fail when an outbreak requires rapid action. The real measure of progress will be a system researchers can use under pressure.
Sources
- WHO: Member States advance negotiations on pathogen access and benefit sharing
- WHO: Intergovernmental Working Group on the Pandemic Agreement
